BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 10348255)

  • 1. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):3-21. PubMed ID: 10348255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies.
    Capizzi R
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):2-17. PubMed ID: 8783661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol).
    Capizzi RL
    Eur J Cancer; 1996; 32A Suppl 4():S5-16. PubMed ID: 8976816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioprotectants: pharmacology and clinical applications of amifostine.
    Dorr RT
    Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):10-3. PubMed ID: 9794995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurologic protection by amifostine.
    DiPaola RS; Schuchter L
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):82-8. PubMed ID: 10348265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioprotective effects of amifostine.
    Wasserman T
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):89-94. PubMed ID: 10348266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amifostine modulation of bleomycin-induced lung injury in rodents.
    Nici L; Calabresi P
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):28-33. PubMed ID: 10348257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amifostine and combined-modality therapeutic approaches.
    Mehta MP
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):95-101. PubMed ID: 10348267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
    Capizzi RL; Scheffler BJ; Schein PS
    Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future development of amifostine as a radioprotectant.
    Werner-Wasik M
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
    Balzarotti M; Grisanti S; Granzow K; Saladini A; Sala A; Nozza A; Molteni A; Passamonti F; Carlo-Stella C; Santoro A; Siena S
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):66-71. PubMed ID: 10348263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amifostine in clinical oncology: current use and future applications.
    Koukourakis MI
    Anticancer Drugs; 2002 Mar; 13(3):181-209. PubMed ID: 11984063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection by amifostine of cyclophosphamide-induced myelosuppression.
    Alberts DS
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):37-40. PubMed ID: 10348259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia.
    List AF
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):61-5. PubMed ID: 10348262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects.
    van der Vijgh WJ; Peters GJ
    Semin Oncol; 1994 Oct; 21(5 Suppl 11):2-7. PubMed ID: 7973774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of amifostine: from cytoprotectant to therapeutic agent.
    Santini V; Giles FJ
    Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemopreventive doses of amifostine confer no cytoprotection to tumor nodules growing in the lungs of mice treated with cyclophosphamide.
    Grdina DJ; Hunter N; Kataoka Y; Murley JS; Milas L
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):22-7. PubMed ID: 10348256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments and emerging options: the role of amifostine as a broad-spectrum cytoprotective agent.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):1-2. PubMed ID: 10348254
    [No Abstract]   [Full Text] [Related]  

  • 20. Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine.
    Castiglione F; Dalla Mola A; Porcile G
    Tumori; 1999; 85(2):85-91. PubMed ID: 10363072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.